EGFR and melanoma: Interrogation of a large number of pan-negative melanoma cell lines for ERBB activity and sensitivity to trametinib or afatinib revealed that this Class II phenotype potentially represents 18.8% of pan-negative melanomas, or ~6% of all melanomas.